Last reviewed · How we verify
NCT07143773: SGL-TX-GFR
SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients
Phase 4 trial testing SGLT-2 inhibitor in Kidney Transplantation Recipients in 88 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | Odense University Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 88 |
| Start date | 1 September 2025 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 August 2027 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- SGLT-2 inhibitor — full drug profile →
- Placebo
Conditions studied
- Kidney Transplantation Recipients — all drugs for Kidney Transplantation Recipients →
- Sodium-Glucose Transporter 2 Inhibitors — all drugs for Sodium-Glucose Transporter 2 Inhibitors →
- Non-Diabetic Patients — all drugs for Non-Diabetic Patients →
- Randomized Controlled Trial — all drugs for Randomized Controlled Trial →
Sponsor
Odense University Hospital
Who can join
18 and older, any sex, with Kidney Transplantation Recipients or Sodium-Glucose Transporter 2 Inhibitors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial investigates whether 18 months of daily SGLT2i (10 mg Forxiga) preserves kidney function and evaluates safety, based on eGFR changes and adverse event occurrence in non-diabetic kidney transplant recipients. The main questions it aims to answer are: * Does SGLT2i versus placebo, as an add-on to standard care, preserve kidney transplant function in non-diabetic recipients? * Is SGLT2i treatment safe for non-diabetic transplant recipients when evaluating adverse events? * Does SGLT2i versus placebo affect the occurrence of urinary tract infections, post-transplant diabetes mellitus (PTDM) and prediabetes incidence, U-ACR, as well as renal and cardiovascular parameters? Researchers will compare a daily dose of SGLT2i (10 mg Forxiga) with a placebo (a look-alike tablet with no active medicine). Kidney transplant recipients who do not have diabetes can take part if they meet the study's requirements. Participants will be randomly assigned to receive either Forxiga or placebo once daily for 18 months. All participants will have check-ups every 3 months, which will include urine tests and blood samples. Neither the participants nor the study doctors will know which treatment they are receiving.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07143773
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SGLT-2 inhibitor
Trials testing the same drug.
- NCT07172971 — Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy · Phase 1 · not yet recruiting
- NCT07272057 — SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes · NA · not yet recruiting
- NCT06905405 — The Use of Advanced Imaging in HFpEF · recruiting
- NCT07325435 — Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists · Phase 4 · active not recruiting
- NCT06753994 — Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors · Phase 1 · recruiting
Other recruiting trials for Kidney Transplantation Recipients
Currently open trials in the same condition.
- NCT07415421 — Parathyroidectomy After Kidney Transplantation · NA · recruiting
- NCT06933355 — Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension · Phase 4 · active not recruiting
- NCT07356388 — FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan · Phase 3 · active not recruiting
- NCT06848816 — Duration of Antibiotic Therapy in Acute Kidney Graft Pyelonephritis (AGPN): Effect on the Risk of Recurrence · active not recruiting
Other Odense University Hospital trials
Trials by the same sponsor.
- NCT07163091 — Bracing After Ankle Fracture · NA · not yet recruiting
- NCT07521696 — Physical Recovery During Bracing After Ankle Fracture (Re-BAF) · NA · not yet recruiting
- NCT07466212 — QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy · not yet recruiting
- NCT07191379 — Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma · Phase 4 · not yet recruiting
- NCT07170085 — Positioning of Children With Acute Respiratory Insufficiency · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07143773 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Odense University Hospital
- Last refreshed: 27 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07143773.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing